Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Acq. announced
Consulting agrmnt
Inv. presentation
PROLOR Biotech, Inc. (PBTH) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/10/2013 EFFECT Form EFFECT - Notice of Effectiveness
09/09/2013 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
09/06/2013 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
09/06/2013 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
09/06/2013 POS AM Form POS AM - Post-Effective amendments for registration statement
08/30/2013 8-K Quarterly results
08/30/2013 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
08/09/2013 10-Q Quarterly Report for the period ended June 30, 2013
07/24/2013 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
07/15/2013 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials
06/12/2013 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans
06/07/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/04/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "PROLOR BIOTECH initiates PIVOTAL phase III trial of ITS Longer-Acting Version of human growth hormone Nes-Ziona, Israel– June 4, 2013 – PROLOR Biotech, Inc. , a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company’ s proprietary version of human growth hormone , in growth hormone deficient adults. PROLOR is developing hGH-CTP to provide growth hormone deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly injections, rather than the daily injections required by current hGH therapy. The initiation of the Phase III clinical trial follows a set of successful Phase II trials showing that hGH-CTP has the potential to be effective when injected once w..."
06/04/2013 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
05/10/2013 10-Q Quarterly Report for the period ended March 31, 2013
05/08/2013 ARS Form ARS - Annual Report to Security Holders
04/29/2013 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
04/25/2013 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
04/25/2013 DEF 14A Form DEF 14A - Other definitive proxy statements
04/24/2013 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
03/15/2013 10-K Annual Report for the period ended December 31, 2012
11/08/2012 10-Q Quarterly Report for the period ended September 30, 2012
08/09/2012 10-Q Quarterly Report for the period ended June 30, 2012
06/07/2012 8-K Form 8-K - Current report
05/17/2012 ARS Form ARS - Annual Report to Security Holders
05/16/2012 SC 13D/A Form SC 13D - General statement of acquisition of beneficial ownership [amend]
05/14/2012 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement between the Company and Jefferies, for itself and as representative of the other underwriters named therein",
"Opinion of Greenberg Traurig, LLP",
"PROLOR BIOTECH Announces PROPOSED Public Offering of Common Stock Nes-Ziona, Israel – May 10, 2012 – PROLOR Biotech, Inc. today announced that it intends, subject to market conditions, to offer and sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager and Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. PROLOR intends to use the net proceeds from this offering for general corporate purposes, which may include research and...",
"PROLOR BIOTECH Announces PRICING OF Public Offering of Common Stock Nes-Ziona, Israel – May 11, 2012 – PROLOR Biotech, Inc. , today announced the pricing of its previously announced underwritten public offering of 6.5 million shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to PROLOR from this offering are expected to be $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by PROLOR. PROLOR has granted the underwriters a 30-day option to purchase up to an aggregate of 975,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on May 16, 2012, subject to customary closing conditions. Jefferies & Company, Inc. is acting as the sole book-running man..."
05/11/2012 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]
05/04/2012 10-Q Quarterly Report for the period ended March 31, 2012
04/27/2012 EFFECT Form EFFECT - Notice of Effectiveness
04/24/2012 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
04/24/2012 DEF 14A Form DEF 14A - Other definitive proxy statements
04/20/2012 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders Nes-Ziona, Israel – April 20, 2012 – PROLOR Biotech, Inc. today announced that it received a letter from NYSE Regulation regarding a late notification to NYSE Amex of the “record date” for this year's Annual Stockholders’ Meeting. April 12, 2012 was set as the record date for PROLOR’ s Annual Meeting, meaning stockholders as of April 12, 2012 are entitled to vote their respective shares at PROLOR's 2012 Annual Meeting, which is scheduled for June 5, 2012. A company listed on the NYSE Amex is required to provide the Exchange with notice of the record date for its Annual Stockholders’ meeting at least 10 days prior to the record date. PROLOR provided late notice of the..."
04/19/2012 8-K Investor presentation
Docs: "Slide Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy